In June 2009 we reported on data suggesting that the monocolonal antibody ipilimumab appeared to be capable of “downstaging” more advanced forms of prostate cancer such that the patients became re-eligible for localized therapy with curative intent. It’s time for an update based on data presented at the Genitourinary Cancers Symposium last Friday and Saturday.
Filed under: Drugs in development, Management, Treatment | Tagged: advanced, down-stageing, ipilimumab, locallly advanced | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site
